Future Perspectives on HER2 ADCs in Gynecological Cancer
Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.
EP: 1.Exploring HER2 as a Pan Tumor Biomarker
EP: 2.HER2 in Breast Cancer: Shaping Treatment in Other Solid Tumors
EP: 3.Expert Insights on HER2-Directed ADCs in Breast Cancer
EP: 4.Targeting HER2 Alterations with ADCs in NSCLC
EP: 5.Landscape Surrounding HER2 ADCs in GI Cancers
EP: 6.Emerging Data for HER2 ADCs in Ovarian Cancer
EP: 7.HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape
EP: 8.HER2 ADCs in Cervical Cancer: A Promising Therapeutic Frontier
EP: 9.Expert Insights on HER2 Testing in Gynecological Cancers
EP: 10.Future Perspectives on HER2 ADCs in Gynecological Cancer
Dr. Ritu Salani and Dr. Martin Dietrich discuss the future of HER2-directed antibody-drug conjugates (ADCs) in gynecologic malignancies and the importance of standardizing testing across cancer sites.
Dr. Salani expresses optimism about the role of ADCs in gynecologic cancers but cautions against grouping all gynecologic malignancies together due to their distinct behaviors and existing standard therapies. She emphasizes the need to carefully consider where ADCs fit into treatment algorithms, such as their potential use as a post-chemotherapy strategy in endometrial cancer or as a second-line option in cervical and ovarian cancers.
Dr. Salani highlights the compelling data in carcinosarcoma, a challenging histology to treat, and suggests that further studies are warranted. She anticipates that ADCs will likely move to the second-line setting across the board, with studies exploring earlier use in HER2-positive patients. Standardizing HER2 testing is crucial to optimize patient selection and ensure appropriate use of these drugs.
Dr. Dietrich echoes Dr. Salani's optimism and notes the surprising prevalence of HER2 positivity across epithelial malignancies when accounting for non-amplified cases. He emphasizes the importance of recognizing ADCs as a pan-tumor treatment option while still maintaining subspecialty expertise.
Both doctors agree that the efficacy and safety of ADCs will guide treatment decisions when multiple biomarkers are present. The inclusion of ADCs in NCCN guidelines for various cancers provides a strong incentive for HER2 testing. They conclude by highlighting the value of cross-disciplinary discussions and the potential for further advancements in HER2-directed therapies.
Summary generated by Claude AI.
